Solid Biosciences Inc.

NasdaqGS:SLDB Stock Report

Market Cap: US$472.7m

Solid Biosciences Balance Sheet Health

Financial Health criteria checks 6/6

Solid Biosciences hat ein Gesamteigenkapital von $144.4M und eine Gesamtverschuldung von $0.0, was einen Verschuldungsgrad von 0% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen $184.7M bzw. $40.4M.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ration/a
CashUS$123.64m
EquityUS$126.48m
Total liabilitiesUS$38.46m
Total assetsUS$164.94m

Recent financial health updates

Recent updates

Solid Biosciences: DMD Treatment Advancement With Next-Generation Capsid

Jan 17

Solid Biosciences to acquire gene therapy company AavantiBio

Sep 30

Analysts Have Lowered Expectations For Solid Biosciences Inc. (NASDAQ:SLDB) After Its Latest Results

Apr 30
Analysts Have Lowered Expectations For Solid Biosciences Inc. (NASDAQ:SLDB) After Its Latest Results

Some Analysts Just Cut Their Solid Biosciences Inc. (NASDAQ:SLDB) Estimates

Apr 28
Some Analysts Just Cut Their Solid Biosciences Inc. (NASDAQ:SLDB) Estimates

We're Keeping An Eye On Solid Biosciences' (NASDAQ:SLDB) Cash Burn Rate

Mar 17
We're Keeping An Eye On Solid Biosciences' (NASDAQ:SLDB) Cash Burn Rate

Solid Biosciences (NASDAQ:SLDB) Is In A Good Position To Deliver On Growth Plans

Oct 28
Solid Biosciences (NASDAQ:SLDB) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About Solid Biosciences' (NASDAQ:SLDB) Cash Burn Rate

Jul 13
We're Not Very Worried About Solid Biosciences' (NASDAQ:SLDB) Cash Burn Rate

We're Hopeful That Solid Biosciences (NASDAQ:SLDB) Will Use Its Cash Wisely

Mar 17
We're Hopeful That Solid Biosciences (NASDAQ:SLDB) Will Use Its Cash Wisely

Soild Bio sinks 13% after Sarepta data misses goal

Jan 08

Solid Biosciences launches $90M private placement

Dec 11

Solid Biosciences: Does Not Look Like A Solid Investment Given Its Unsatisfactory Trial Data

Nov 10

Financial Position Analysis

Kurzfristige Verbindlichkeiten: SLDBDie kurzfristigen Aktiva des Unternehmens ($148.3M) übersteigen seine kurzfristigen Passiva ($15.8M).

Langfristige Verbindlichkeiten: SLDBDie kurzfristigen Vermögenswerte des Unternehmens ($148.3M) übersteigen seine langfristigen Verbindlichkeiten ($24.6M).


Debt to Equity History and Analysis

Verschuldungsgrad: SLDB ist schuldenfrei.

Schulden abbauen: SLDB hat in den letzten 5 Jahren keine Schulden gemacht.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stabile Start- und Landebahn für Bargeld: SLDB auf der Grundlage seines derzeitigen freier Cashflows über eine ausreichende Liquiditätsreserve für mehr als ein Jahr verfügt.

Vorhersage Cash Runway: SLDB verfügt über eine ausreichende Liquiditätsreserve für 1.4 Jahre, wenn der freie Cashflow weiterhin mit historischen Raten von 8.3% pro Jahr abnimmt.


Discover healthy companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.